# Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

Study · id `cardio:ct-nct03332771` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03332771](<https://clinicaltrials.gov/study/NCT03332771>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03332771

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 954 participants.

## Technical summary

Registry record NCT03332771. Randomized; quadruple masking; primary purpose treatment. Start 2017-12-01 (actual); primary completion 2019-08-06 (actual). Results posted on 2021-05-11.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 954 participants (enrolled count; ClinicalTrials.gov record NCT03332771, source copy `cardio:ctgov-nct03332771-2021-05-11`, retrieved 2026-10-26)
- Started: 2017-12-01 (actual) (ClinicalTrials.gov record NCT03332771, source copy `cardio:ctgov-nct03332771-2021-05-11`, retrieved 2026-10-26)
- Primary completion: 2019-08-06 (actual) (ClinicalTrials.gov record NCT03332771, source copy `cardio:ctgov-nct03332771-2021-05-11`, retrieved 2026-10-26)
- Completion: 2019-09-06 (actual) (ClinicalTrials.gov record NCT03332771, source copy `cardio:ctgov-nct03332771-2021-05-11`, retrieved 2026-10-26)
- Results first posted: 2021-05-11 (ClinicalTrials.gov record NCT03332771, source copy `cardio:ctgov-nct03332771-2021-05-11`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Hungary; Slovakia (ClinicalTrials.gov record NCT03332771, source copy `cardio:ctgov-nct03332771-2021-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03332771-2021-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
- Acronym: SOTA-GLIM
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Sotagliflozin (SAR439954)
- Intervention (Drug): Glimepiride
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Lead sponsor: Lexicon Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Lexicon Pharmaceuticals (`cardio:org-lexicon-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: 2563c9fb63eac4ba586521af143566f8fca057dee07b58914769f35c55636ceb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
